These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22511448)

  • 1. Introduction to the genetics and biology of interleukin-28B.
    Urban T; Charlton MR; Goldstein DB
    Hepatology; 2012 Jul; 56(1):361-6. PubMed ID: 22511448
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical utility of interleukin-28B testing in patients with genotype 1.
    Lai M; Afdhal NH
    Hepatology; 2012 Jul; 56(1):367-72. PubMed ID: 22511388
    [No Abstract]   [Full Text] [Related]  

  • 3. Lost in translation? IL28B's discovery and the journey back to the patient.
    Clark PJ; Muir AJ
    Hepatology; 2012 Jul; 56(1):5-8. PubMed ID: 22511499
    [No Abstract]   [Full Text] [Related]  

  • 4. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
    Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
    Kaohsiung J Med Sci; 2017 Oct; 33(10):510-515. PubMed ID: 28962822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.
    López-Rodríguez R; Hernández-Bartolomé Á; Borque MJ; Rodríguez-Muñoz Y; Martín-Vílchez S; Trapero-Marugán M; García-Buey L; Muñoz de Rueda P; Rodrigo L; Vidal-Castiñeira JR; Salmerón J; Moreno-Otero R; Sanz-Cameno P
    Genes Immun; 2013; 14(5):317-24. PubMed ID: 23615070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.
    Arends JE; Fransen JH; Hoepelman AI; van Baarle D
    Int J Antimicrob Agents; 2011 Dec; 38(6):538-9. PubMed ID: 21974859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
    J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.
    Asselah T; De Muynck S; Broët P; Masliah-Planchon J; Blanluet M; Bièche I; Lapalus M; Martinot-Peignoux M; Lada O; Estrabaud E; Zhang Q; El Ray A; Vidaud D; Ripault MP; Boyer N; Bedossa P; Valla D; Vidaud M; Marcellin P
    J Hepatol; 2012 Mar; 56(3):527-32. PubMed ID: 21951981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
    Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
    Chu TW; Kulkarni R; Gane EJ; Roberts SK; Stedman C; Angus PW; Ritchie B; Lu XY; Ipe D; Lopatin U; Germer S; Iglesias VA; Elston R; Smith PF; Shulman NS
    Gastroenterology; 2012 Apr; 142(4):790-5. PubMed ID: 22248659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
    Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
    J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
    Seto WK; Tanaka Y; Liu K; Lai CL; Yuen MF
    Am J Gastroenterol; 2011 May; 106(5):1007-8. PubMed ID: 21540909
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
    Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
    Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C.
    Orlent H; Hansen B; Janssen HL; De Knegt RJ
    Dig Liver Dis; 2015 Jan; 47(1):87-8. PubMed ID: 25308611
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4.
    Rady NH; Darwish RK; Mogahed EA; Mandour IA; Abo Youssef H; Sharaf SA; El-Karaksy HM
    Cytokine; 2015 Oct; 75(2):349-55. PubMed ID: 25936570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C pharmacogenetics: state of the art in 2010.
    Afdhal NH; McHutchison JG; Zeuzem S; Mangia A; Pawlotsky JM; Murray JS; Shianna KV; Tanaka Y; Thomas DL; Booth DR; Goldstein DB;
    Hepatology; 2011 Jan; 53(1):336-45. PubMed ID: 21254181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.